AI Summary HCC surveillance is regular testing to find hepatocellular carcinoma, the most common liver cancer, early, since it often causes no symptoms. Guidelines recommend an ultrasound plus an AFP blood test about every six months for people with cirrhosis and some with chronic hepatitis B. AFP alone cannot diagnose cancer. An abnormal result usually leads to contrast CT or MRI, sometimes a biopsy. If HCC is confirmed, treatment options include surgery, local therapies, and transplant.
Source: www.liverdirectory.com
Medically Reviewed.
HCC surveillance means regular testing to look for hepatocellular carcinoma, the most common type of liver cancer, in people who are at high risk. Early liver cancer often causes no symptoms, so doctors check on a schedule, usually with an ultrasound and a blood test.
This page explains who needs surveillance, how tumor marker blood tests and imaging work together, and what usually happens if a result looks abnormal.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
HIGH-RISK LIVER DISEASE
Surveillance is meant for people whose liver cancer risk is high enough to justify regular testing. Your liver specialist weighs the benefits and harms for you. Guidelines recommend surveillance for:
TUMOR MARKERS AND IMAGING
Surveillance uses two kinds of tests that work together: a blood test for tumor markers and an imaging scan of the liver. Each child page explains one group in detail.
Tumor markers are substances in the blood that can rise when a liver tumor is present. The one used most often is alpha-fetoprotein (AFP). Some guidelines also use AFP-L3 and des-gamma-carboxy prothrombin (DCP, also called PIVKA-II). A high level raises suspicion and prompts closer imaging, but a marker alone cannot confirm cancer.
Explore individual tumor marker tests:
An abdominal ultrasound is the standard surveillance scan. It is paired with an AFP blood test about every six months. If the liver is hard to see on ultrasound, guidelines recommend contrast-enhanced CT or MRI instead. The same scans are used to confirm a suspicious finding.
Explore individual imaging tests:
SURVEILLANCE TEST COMPARISON
This overview shows how each test fits into surveillance, diagnosis, or both.
| Test | What It Does | Role in Liver Cancer Care |
|---|---|---|
| Abdominal ultrasound | Uses sound waves to look for masses in the liver | Routine surveillance, usually every six months with AFP |
| AFP blood test | Measures a tumor marker in the blood | Added to ultrasound for surveillance; cannot diagnose cancer on its own |
| AFP-L3 and DCP (PIVKA-II) | Measure additional tumor markers | Used with ultrasound in some guidelines, such as for monitoring people with prior HCC |
| Multiphase CT or MRI with contrast | Shows how a spot takes up and clears contrast dye | Confirms HCC in people with cirrhosis or chronic hepatitis B; used when ultrasound views are poor |
| Liver biopsy | Examines a small tissue sample under a microscope | Confirms the diagnosis when imaging is unclear; tissue can be tested for genetic changes |
Your doctor chooses tests based on your liver condition, scan quality, and prior results.
LIVER TEST RESOURCE
Keep a plain-language guide to common liver tests and what they show.
FOLLOW-UP AFTER ABNORMAL TESTS
An abnormal result does not always mean cancer. It means your care team needs a closer look.
A raised AFP or another tumor marker can increase suspicion, especially when a scan shows an unclear spot. Doctors then order closer imaging or, in some cases, a biopsy. Markers add to the overall risk picture but do not decide the diagnosis alone.
In people with cirrhosis or chronic hepatitis B, HCC can often be diagnosed without a biopsy. Guidelines base this on contrast-enhanced multiphase CT or MRI. HCC typically lights up in the early (arterial) phase and then washes out in later phases. Radiologists grade these findings with a system called LI-RADS.
A spot that is not clearly cancer is called an indeterminate liver nodule. Guidelines suggest contrast-enhanced imaging every 3 to 6 months for most people. Nodules of 2 cm or larger are more likely to be cancer. Some nodules lose their suspicious look over time.
If HCC is confirmed, treatment depends on the condition of the liver, the size, location, and number of tumors, whether cancer has spread, and your overall health. Options include surgery, local therapies, and transplant.
Diet plays an important role in supporting liver health, whatever your test results show.
Common Questions
No. An AFP blood test cannot diagnose liver cancer on its own. Guidelines advise against using AFP alone, or liquid biopsy, to diagnose HCC because these tests are not accurate enough. A high AFP raises suspicion and usually leads to closer imaging. Imaging, and sometimes a biopsy, confirms the diagnosis. AFP is most useful as part of surveillance, where it is added to an ultrasound about every six months.
Yes, if you have cirrhosis. Clearing the hepatitis C virus does not remove the cirrhosis, and cirrhosis remains a major risk factor for HCC. Guidelines say people with cirrhosis need lifelong surveillance even after the virus is cleared. Your liver specialist can tell you which tests to have and how often.
Your doctor may switch to contrast-enhanced CT or MRI. Ultrasound can give a poor view of the liver in some people, and guidelines recommend these scans in that case. Both scans use contrast dye to show the liver in more detail. Your doctor chooses the test based on your liver condition, scan quality, and prior results.
Not necessarily. Some spots turn out to be benign, and some lose their suspicious look over time. Your doctor will usually order contrast-enhanced CT or MRI. These scans show how a spot takes up and clears contrast dye, which helps tell benign nodules from HCC. If a spot is still unclear, it is called an indeterminate nodule, and most people have contrast-enhanced imaging every 3 to 6 months to watch for changes. In people with cirrhosis or chronic hepatitis B, HCC can often be diagnosed from these scans without a biopsy.
No. Surveillance is meant for people whose risk of HCC is high enough to justify regular testing, such as people with Child-Turcotte-Pugh class A or B cirrhosis. Guidelines recommend against it for people with Child-Turcotte-Pugh class C cirrhosis who cannot have a transplant, and for people with life-limiting conditions that treatment cannot fix. Your doctor weighs the benefits and harms for you, so ask whether surveillance fits your situation.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
